This study is currently not recruiting participants.

An Uncontrolled Observational Study Providing Continued Access to Care of a Generic Liposome Encapsulated Doxorubicin Hydrochloride Formulation in Subjects with Epithelial Ovarian Carcinoma who Have Failed Platinum-Based Chemotherapy

Study on Continued Access to Investigational Medication for Prior Participants

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to provide continued access to treatment for US subjects who participated in the single-dose bioavailability (BA) study (TOL2649D), assuring that they continue to receive their clinically indicated therapy with liposomal doxor

Detailed description of study

The purpose of this study is to provide continued access to treatment for US subjects who participated in the single-dose bioavailability (BA) study (TOL2649D), assuring that they continue to receive their clinically indicated therapy with liposomal doxor

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ovarian Cancer
  • Age: 100 years or below
  • Gender: All

This study investigates the continued access to an investigational medication for participants in a previous single-dose bioavailability study. The investigational medication is being provided to ensure that participants continue to receive the treatment that is clinically indicated for them.

Participants in this study will receive the investigational medication as part of their ongoing therapy. The study aims to maintain the therapeutic regimen that was determined to be appropriate in the earlier study.

  • Who can participate: Participants must have been involved in the prior single-dose bioavailability study to be eligible.
  • Study details: Participants will receive the investigational medication as part of their ongoing therapy. This ensures continued access to the necessary treatment regimen determined in the earlier study.
Updated on 19 Feb 2024. Study ID: 1209009475

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team